Press Releases

11.16.2017

Pfizer Receives FDA Approval for SUTENT® (sunitinib malate) as First and Only Adjuvant Treatment for Adult Patients at High Risk of Recurrent Renal Cell Carcinoma

11.15.2017

COMBACTE Adds a New Project to its Consortium: COMBACTE-CDI

11.15.2017

UC San Diego Center for Microbiome Innovation Announces Pfizer as Corporate Member

11.13.2017

Pfizer Names Albert Bourla Chief Operating Officer

11.10.2017

BMS-Pfizer Alliance To Unveil Real-World Data Analyses - Cost, Safety and Comparative Effectiveness Findings Associated with Oral Anticoagulants in Non-Valvular Atrial Fibrillation

11.10.2017

Pfizer Sells Its 49% Equity Share in Hisun-Pfizer Pharmaceuticals

11.07.2017

Spark Therapeutics and Pfizer Amend License Agreement for Investigational SPK-9001 in Hemophilia B

11.01.2017

Encycle Therapeutics announces discovery collaboration with Pfizer Inc.

10.31.2017

Pfizer Reports Third-Quarter 2017 Results

10.29.2017

One Year Maintenance and Switching Data in Patients with Crohn’s Disease Support the Use of INFLECTRA®* (infliximab CT-P13) in IBD1

10.16.2017

New Ulcerative Colitis Data for XELJANZ® (tofacitinib) at Upcoming Gastroenterology Congresses

10.16.2017

Pfizer Presents Full Results from Phase 2 Study of Next-Generation Investigational ALK-Inhibitor Lorlatinib in ALK-Positive and ROS1-Positive Advanced Non-Small Cell Lung Cancer